{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-178857","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2022-06-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.943814+00:00","generated_at":"2026-06-24T23:57:24.746760+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"confidence":"high","headline":"Aura Biosciences reports positive retrospective data for AU-011 in choroidal melanoma vs. radiotherapy","bullets":["Belzupacap sarotalocan showed statistically significant vision preservation at 2 years vs. plaque radiotherapy (logMAR p=0.0094).","Radiotherapy patients lost ≥3 lines of vision in a majority by 2 years; ≥6 lines by 3 years.","Data from 43 AU-011 patients vs. 150 matched radiotherapy controls (tumor edge within 3.0 mm of fovea).","Mean follow-up for AU-011 was 15.6 months; study is retrospective and hypothesis-generating.","Phase 2 trial (suprachoroidal) ongoing; pivotal trial expected to initiate by end of 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-178857","json":"https://secwatch.observer/filing/0001193125-22-178857.json","markdown":"https://secwatch.observer/filing/0001193125-22-178857.md","text":"https://secwatch.observer/filing/0001193125-22-178857.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000119312522178857/0001193125-22-178857-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000119312522178857/d292968d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T23:57:24.746760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}